## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

| ACADIA P<br>Form 4<br>June 17, 200  | HARMACEUTIC  | CALS INC                                     | 2  |   |   |  |  |  |                          |  |  |
|---|--|--|--|---|---|--|--|--|--------------------------|--|--|
| FORN<br>Check th<br>if no lon<br>subject t<br>Section<br>Form 4 o<br>Form 5<br>obligatio<br>may con<br>See Instr<br>1(b). | <b>A 4</b> UNITED<br>his box<br>ager<br>to<br>16.<br>bor<br>Filed pur<br>Section 17( | <b>MENT O</b><br>rsuant to S<br>(a) of the 1 | Wa<br>F CHAN<br>Section<br>Public U  | ashington<br>NGES IN<br>SECUI<br>16(a) of th            | , D.C. 20<br>BENEF<br>RITIES<br>ne Securi<br>ding Con | )549<br>ICIAL<br>ties Exc<br>npany A             | GE COMMISSION<br>OWNERSHIP OF<br>change Act of 1934,<br>Act of 1935 or Section<br>of 1940                                      | OMB<br>Number:<br>Expires:<br>Estimated<br>burden hou<br>response  | urs per                  |  |  |
| 1. Name and Address of Reporting Person <u>*</u><br>KAPLAN LESTER J PH D  |  |  | 2. Issuer Name and Ticker or Trading<br>Symbol<br>ACADIA PHARMACEUTICALS<br>INC [ACAD] |   |   | Issuer   | 5. Relationship of Reporting Person(s) to<br>Issuer<br>(Check all applicable)  |  |                          |  |  |
|   | DIA<br>CEUTICALS INC<br>O VALLEY   | Middle)<br>C., 3911                          |  | of Earliest T<br>Day/Year)<br>2008                      | ransaction  |  | X Director<br>Officer (give<br>below)  |  | % Owner<br>her (specify  |  |  |
|   |  |  |  | 4. If Amendment, Date Original<br>Filed(Month/Day/Year) |   |  | Applicable Line)<br>_X_ Form filed by<br>Form filed by I   | 6. Individual or Joint/Group Filing(Check<br>Applicable Line)<br>_X_ Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person |                          |  |  |
| (City)  | (State)  | (Zip)  | Tał  | ole I - Non-l   | Derivative  | Securiti   | ies Acquired, Disposed o   | f. or Beneficia  | llv Owned                |  |  |
| 1.Title of<br>Security<br>(Instr. 3)  | 2. Transaction Date<br>(Month/Day/Year)  | 2A. Deem<br>Execution<br>any<br>(Month/Da    | ed<br>Date, if   | 3.<br>Transactio<br>Code<br>(Instr. 8)<br>Code V        | 4. Securit<br>mAcquired<br>Disposed<br>(Instr. 3,     | ies<br>(A) or<br>of (D)<br>4 and 5)<br>(A)<br>or | 5. Amount of Securities Beneficially Owned   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I)<br>(Instr. 4)   | 7. Nature of<br>Indirect |  |  |
| Reminder: Rej   | port on a separate line  | e for each cl                                | ass of sec   | purities bene   | Perso<br>inforr<br>requi                              | ons who<br>nation o<br>red to re                 | etly or indirectly.<br>The respond to the collect<br>contained in this form<br>espond unless the for<br>urrently valid OMB cor | are not<br>m   | SEC 1474<br>(9-02)       |  |  |

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. 5. Number of<br>TransactiorDerivative<br>Code Securities<br>(Instr. 8) Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) |         | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                     | 8<br>11<br>25<br>() |
|---|---|---|---|--|---------|--|--------------------|---|-------------------------------------|---------------------|
|   |   |   |   | Code V   | (A) (D) | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |                     |
| Stock<br>Option<br>(right to<br>buy)                | \$ 8.49   | 06/13/2008                              |   | A  | 10,000  | (1)  | 06/12/2018         | Common<br>Stock   | 10,000                              |                     |
| Stock<br>Option<br>(right to<br>buy)                | \$ 8.49   | 06/13/2008                              |   | A  | 8,833   | <u>(1)</u>   | 06/12/2018         | Common<br>Stock   | 8,833                               |                     |

## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

| <b>Reporting Owner Name / Address</b>   |          | Relationships |         |       |  |  |  |  |
|---|----------|---------------|---------|-------|--|--|--|--|
|   | Director | 10% Owner     | Officer | Other |  |  |  |  |
| KAPLAN LESTER J PH D<br>C/O ACADIA PHARMACEUTICALS INC<br>3911 SORRENTO VALLEY BOULEVARI<br>SAN DIEGO, CA 92121 | · X      |               |         |       |  |  |  |  |
| Signatures  |          |               |         |       |  |  |  |  |
| /s/ Uli Hacksell, 06/17/<br>attorney-in-fact  | /2008    |               |         |       |  |  |  |  |
| **Signature of Reporting Person Dat   | e        |               |         |       |  |  |  |  |
| Explanation of Responses:   |          |               |         |       |  |  |  |  |

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.
- (2) The Reporting Person has elected to convert annual retainer fees of \$25,000 into a stock option under the terms of the Issuer's Outside Director Compensation Program.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S